Program for screening and preventing diabetic retinopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program aims to address the high rates of diabetic retinopathy (DR) among diabetes patients in China by implementing an efficient workflow for early detection and management of the condition. Utilizing deep learning technology, the program seeks to enhance the sensitivity and specificity of DR screening through automated grading systems. Participants will be recruited from various medical institutes to explore the prevalence of DR and gather data on genetics, biomarkers, and lifestyle factors that may contribute to the disease. The ultimate goal is to establish a referral system for timely treatment and long-term follow-up of DR patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Meet the diagnostic criteria for type 2 diabetes according to the World Health Organization (WHO) in 1999; Type 1 diabetes, single gene mutation diabetes, secondary diabetes caused by pancreatic damage, Cushing's syndrome, thyroid dysfunction, or acromegaly;
* Subjects from other medical institutes are diabetes, non-diabetic patients and healthy participants who are invited to participate in the study.

Exclusion Criteria:

* Those who have a history of drug abuse;
* Sexually transmitted diseases such as AIDS and syphilis, and infectious diseases such as viral hepatitis and tuberculosis which are at active phase;
* Any condition that the investigator think that the subject is not suitable for participating in the study.

For detailed In-/Ex-clusion criteria please see the study protocol.

Where it's running

• Ruijin hospital, Shanghai Jiao-Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting
• Shanghai Jiao-Tong University School of Medicine
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Guang Ning, MD,PHD — Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China
• Study coordinator: Guang Ning, MD,PHD
• Email: guangning@medmail.com.cn
• Phone: 8621-64370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy

  This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.

  Recruiting Phase 4 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07843849

• Automated detection of diabetic retinopathy lesions in fundus photos

  This study tests a smart imaging system within the DDART device to see if it can reliably spot diabetic retinopathy lesions in color fundus photographs.

  Recruiting Democritus University of Thrace · Alexandroupoli · NCT07758582

• Retinal microvascular changes in diabetic retinopathy measured with OCTA

  This observational study tests how retinal blood vessel patterns seen on OCTA relate to vision and blood sugar control in adults with diabetic retinopathy.

  Recruiting Sohag University · Sohag · NCT07747428

• MK-8748 vs. aflibercept for diabetic macular edema

  This trial tests whether the investigational medicine MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in adults with diabetes.

  Recruiting at 20 sites Phase 3 Merck Sharp & Dohme LLC · Long Beach, California and 19 other locations · NCT07705607

• MK-8748 vs aflibercept for diabetic macular edema

  This trial tests whether MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in people with diabetes.

  Recruiting at 35 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 34 other locations · NCT07705555

• Surabgene Lomparvovec in the Suprachoroidal Space for Diabetic Retinopathy

  This study tests a one-time gene therapy called surabgene lomparvovec to see if it can help adults with non-proliferative diabetic retinopathy avoid vision-threatening events.

  Recruiting at 40 sites Phase 2/3 AbbVie · Mesa, Arizona and 39 other locations · NCT07592273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.